Search
Palvella Therapeutics Inc
PVLAAdd to Watchlist
114.240USD
-4.730-3.98%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.64BMarket Cap
LossP/E TTM
More Details of Palvella Therapeutics Inc Company
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Palvella Therapeutics Inc Info
Ticker SymbolPVLA
Company namePalvella Therapeutics Inc
IPO dateDec 18, 2014
CEOKaupinen (Wesley H)
Number of employees14
Security typeOrdinary Share
Fiscal year-endDec 18
Address353 W. Lancaster Avenue
CityWAYNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19087
Phone14842531461
Websitehttps://palvellatx.com/
Ticker SymbolPVLA
IPO dateDec 18, 2014
CEOKaupinen (Wesley H)
Company Executives of Palvella Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Tadd S. Wessel
Mr. Tadd S. Wessel
Independent Director
Independent Director
477.21K
--
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
201.13K
--
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
53.69K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Matthew E. Korenberg
Mr. Matthew E. Korenberg
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Jeffrey (Jeff) Martini, Ph.D.
Dr. Jeffrey (Jeff) Martini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Todd C. Davis
Mr. Todd C. Davis
Independent Director
Independent Director
--
--
Dr. David W. Osborne, Ph.D.
Dr. David W. Osborne, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Tadd S. Wessel
Mr. Tadd S. Wessel
Independent Director
Independent Director
477.21K
--
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
201.13K
--
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
53.69K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Matthew E. Korenberg
Mr. Matthew E. Korenberg
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
6.22%
BVF Partners L.P.
6.13%
Kaupinen (Wesley H.)
5.76%
Frazier Life Sciences Management, L.P.
5.04%
First Light Asset Management, LLC
4.94%
Other
71.91%
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
6.22%
BVF Partners L.P.
6.13%
Kaupinen (Wesley H.)
5.76%
Frazier Life Sciences Management, L.P.
5.04%
First Light Asset Management, LLC
4.94%
Other
71.91%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
25.54%
Investment Advisor
23.56%
Hedge Fund
20.39%
Individual Investor
11.65%
Private Equity
6.89%
Research Firm
1.60%
Sovereign Wealth Fund
0.84%
Venture Capital
0.83%
Bank and Trust
0.45%
Other
8.25%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
267
11.89M
82.90%
+1.54M
2025Q4
203
9.67M
81.68%
+2.49M
2025Q3
145
6.92M
62.61%
+1.10M
2025Q2
113
8.02M
72.53%
+1.47M
2025Q1
119
7.23M
65.51%
+2.66M
2024Q4
118
6.14M
54.71%
+5.00M
2024Q3
118
806.99K
64.03%
-218.37K
2024Q2
120
474.51K
38.85%
-479.71K
2024Q1
135
564.53K
48.12%
-430.81K
2023Q4
149
574.40K
48.95%
-409.12K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Suvretta Capital Management, LLC
892.40K
7.03%
+70.00K
+8.51%
Dec 31, 2025
BVF Partners L.P.
879.01K
6.93%
-282.24K
-24.30%
Dec 31, 2025
Kaupinen (Wesley H.)
1.61M
12.67%
--
--
Apr 14, 2025
Frazier Life Sciences Management, L.P.
722.40K
5.69%
--
--
Dec 31, 2025
First Light Asset Management, LLC
709.14K
5.59%
+167.60K
+30.95%
Dec 31, 2025
Jennison Associates LLC
387.48K
3.05%
+280.57K
+262.44%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
507.39K
4%
+57.99K
+12.91%
Dec 31, 2025
Federated Hermes Global Investment Management Corp.
368.04K
2.9%
+28.99K
+8.55%
Dec 31, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco Dorsey Wright SmallCap Momentum ETF
0.51%
ALPS Medical Breakthroughs ETF
0.37%
iShares Micro-Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
iShares Russell 2000 Growth ETF
0.03%
Global X Russell 2000 ETF
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
View more
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.51%
ALPS Medical Breakthroughs ETF
Proportion0.37%
iShares Micro-Cap ETF
Proportion0.11%
Vanguard US Momentum Factor ETF
Proportion0.1%
iShares Russell 2000 Growth ETF
Proportion0.03%
Global X Russell 2000 ETF
Proportion0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Date
Ex-dividend Date
Type
Ratio
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
